Long-term therapeutic strategies in HIV

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 16, Issue SUPPL. 1, 1997, Pages

  Miles, Steven A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Antiretroviral therapy; Cytokines; Fatigue; HIV; Non Nucleoside analogues; Nucleoside analogues; Oncologic model; Protease inhibition

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER GROWTH; CONFERENCE PAPER; FATIGUE; GROWTH INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; PRIORITY JOURNAL; PROTEINASE INHIBITION; QUALITY OF LIFE; TREATMENT PLANNING; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; QUALITY OF LIFE; SALVAGE THERAPY; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030862169     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199701001-00006     Document Type: Article

References (25)

1. Stockdale FE. Cancer growth and chemotherapy. In: Dale DC, Federman DD, Cassel CK, et al., eds. Scientific American medicine. New York: Scientific American, 1996; section 12, chapter V:1-19.
2. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996;124:984-94.
3. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;333: 450-1.
4. DeVita VT Jr. Principles of cancer management: chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:333-47.
5. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
6. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
7. Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996;124:1086-8.
8. + cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
9. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993;119:786-93.
10. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:118-25.
11. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) [Abstract]. Proc Third Conf Retroviruses Opportunistic Infections, 1996;LB7.
12. Saag MS, Holodniy M, Kuritzkes Dr, et al. HIV viral load markers in clinical practice. Nature Med 1996;2:625-9.
13. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
14. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
15. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
16. Coombs RW, Welles SL, Hooper C, et al. for the AIDS Clinical Trials Group (ACTG) 116B/117 Study Team and the ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-12.
17. Welles SL, Jackson JB, Yen-Lieberman B, et al. for the AIDS Clinical Trials Group Protocol 116A/116B/117 Team. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996;174:696-703.
18. Carpenter CCJ, Fischl MA, Hammer SM, et al. for the International AIDS Society-USA. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996; 276:146-54.
19. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
20. Gazzard B, on behalf of the International Coordinating Committee. Further results from European/Australian Delta trial [Abstract]. Proc Third Conf Retroviruses Opportunistic Infections, 1996;LB5a.
21. Pollard R, Peterson D, Hardy D, et al. Antiviral effect and safety of stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blinded trial [Abstract]. Proc Third Conf Retroviruses Opportunistic Infections, 1996;197.
22. Staszewski S, Loveday C, Picazo JJ, et al. for the Lamivudine European HIV Working Group. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:111-7.
23. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
24. Mellors JW. Clinical implications of resistance and cross-resistance to HIV protease inhibitors. Infect Med 1996;13(suppl F):32-8.
25. D'Aquila RT, Hughes MD, Johnson VA, et al., and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:1019-30.